Kallistatin is a new inhibitor of angiogenesis and tumor growth.
about
The Potential Role of Kallistatin in the Development of Abdominal Aortic AneurysmProtection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stressKallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakageLiver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver.Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatinAltered protein expression at early-stage rat hepatic neoplasia.SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overloadKruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression.Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation.Plasma kallistatin in critically ill patients with severe sepsis and septic shock.Plasma kallistatin levels in patients with severe community-acquired pneumonia.Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signalingBlocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family.High-resolution functional proteomics by active-site peptide profilingKallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activationDepletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling.Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling.Thyroid hormone and COUP-TF1 regulate kallikrein-binding protein (KBP) gene expression.Effective and sustained delivery of hydrophobic retinoids to photoreceptorsNovel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells.Heparin impairs angiogenesis through inhibition of microRNA-10b.Angiogenesis in diabetes and obesityIncreased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement.Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsisThe plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndromeManipulating angiogenesis in medicine.The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis.Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutininKallikrein-kinin in stroke, cardiovascular and renal disease.Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression.Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosisSERPINA4 is a novel independent prognostic indicator and a potential therapeutic target for colorectal cancer.Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway.Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis.Adenoviral vector-based strategies for cancer therapy.Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells.Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
P2860
Q26741231-BF7D2D98-D357-46FA-8BC8-A180290D3F34Q28539856-10086A0C-AABB-4BBB-BBB5-DA70C010F675Q28577418-67DBE38A-7919-485A-89E5-815E219503ECQ30826136-562922E6-67A9-4B7C-A22E-05FE08EC1B0FQ30983984-113F0445-CD62-44E5-8247-B915191CD614Q33271648-DCEF4C8A-7305-4FDA-8FD3-F25398AC0A37Q33396454-F3A2435C-1351-4F21-AD32-DCF0136716DCQ33512668-595CA8B1-A45F-40AE-B1E1-4ACB0924D8FEQ33699388-A1746F58-EDC1-4790-BDB4-79D038CAEA66Q33725117-B2F207EE-91AC-4EC9-8A80-89BF6FB26ED1Q33752812-01B62C90-52C9-47F8-899D-6ED71C011D38Q33787188-B7BCDBB5-FAAE-4F77-8FB5-7AEF74E00635Q33859420-A8E628ED-63AE-46B3-A671-0B4194C68716Q33935044-B694279E-D47F-4E3D-8B3E-50A44389DEFDQ33939375-CF888043-F1D6-4A61-A3D6-1D3B54F99083Q34070667-68829B87-296E-44F1-8729-2B38A2FDC40AQ34289034-4CACC02B-C713-4543-A52A-1549EE5FF4A5Q34357797-8A99FD8E-4124-4C76-94E2-8B3F3071D1FEQ34578472-37A6561F-8B43-4676-815C-B78D3522420FQ34702182-81E75786-7317-4FE1-8B0D-32259A36F412Q35070827-C1741942-1A2A-417D-BA55-672CD04DD202Q35128227-5ED34BE2-3938-46B7-9395-132D1D379A9CQ35153884-C09EE11C-1F42-4E60-AE5F-1249A0CA2E46Q35555319-A18B8DB2-F008-484C-AA14-CBE9EC1EF257Q35654838-47B52D4A-699B-4E9E-80CC-B5C099BEE661Q35673497-3C519C13-DD2C-4BA2-BE99-736DAC500551Q35743851-63749F2E-4C5F-47E9-B4B6-83BF477F9321Q35861497-9696EDE0-7F66-47A3-8E80-9492F9733F36Q35877298-45B5061F-4E7B-4AAF-A79E-DC0FE1C80265Q35960792-6976A11E-5910-4FC4-840C-4367E9C7E11FQ36011348-505BFA88-E97E-4759-88B6-EDFF1EC5EF89Q36029511-DBCAC077-7F96-46F2-81F4-30CFD5CB90B0Q36237963-6B800263-2834-4C11-ACD9-385268EA88A3Q37215516-D6211FC1-5409-429A-ACC0-129F7CCAFE2DQ37263454-32F1CC8D-CA92-44CF-8B66-2D1A60CCBFAFQ37333523-ADEF9A10-197E-4AAE-B631-1E444065A2E6Q37370247-5E3DF024-40BF-4F25-9049-5A4B45F0B50AQ37409025-8C3D4D73-C025-4D4C-AED4-F2C0EAD5718AQ37466518-BD20DB30-22CE-435D-9D4C-D757B3768331Q37697813-B37D4840-C690-4074-BA18-DD1AD4B5E11A
P2860
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@ast
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@en
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@nl
type
label
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@ast
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@en
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@nl
prefLabel
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@ast
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@en
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@nl
P2093
P1433
P1476
Kallistatin is a new inhibitor of angiogenesis and tumor growth.
@en
P2093
Julie Chao
Robert Q Miao
P304
P356
10.1182/BLOOD-2002-01-0185
P407
P577
2002-11-01T00:00:00Z